Unlocking neurogenesis: PRGF Regenerative Therapy and the role of Tau Protein in Neurodegenerative Disease Models

Abstract

Alzheimer's disease (AD) is a neurological condition characterized by persistent cognitive impairment with few treatment options available. Platelet-rich plasma (PRP) and platelet-rich growth factors (PRGF), produced from human blood, have shown promise in treating a variety of neurological disorders. However, their use in Alzheimer's disease is underexplored, particularly in chemically produced models. This study looks at the therapeutic potential of PRGF and PRP in a chemically induced Alzheimer's mouse model using aluminum chloride (AlCl3), with a particular emphasis on the novel use of intranasal PRGF administration. This study to explore and compare the effects of PRGF and PRP in an Alzheimer's disease chemical model. Behavioral assessments were performed to evaluate cognitive deficits, memory retention, and spatial learning. The Y-maze and Elevated Plus Maze (EPM) tests demonstrated significant cognitive improvements in the PRGFtreated mice. PRGF administration resulted in enhanced memory performance and cognitive flexibility, with higher number of alterations and entries to novel arm. Additionally, PRGF-treated mice exhibited reduced anxiety-like behavior in the EPM. These findings suggest that PRGF treatment significantly improves cognitive abilities and memory retention however do not fully restore and cannot be used confidently in treatment. Histological analysis of the frontal cortex, cerebral cortex, hippocampus, dentate gyrus (DG) region, and liver was conducted following behavioral assessments to There were no significant improvements in cellular integrity observed in either the PRGF or PRP treated groups, indicating less to no neuroprotection and potential reversal of AlCl3-induced damage